Download Corporate Fact Sheet - Corporate

Corporate Fact Sheet
Overview
Luminex® Corporation (NASDAQ: LMNX) develops,
manufactures and markets a proprietary technology
with applications throughout the life-sciences industry,
including clinical diagnostics. This industry depends
on a broad range of tests, known as “bioassays,” to
discover new drugs, identify new biological pathways
or assist in diagnosis and/or monitoring of diseases.
The in-house experts at Luminex have developed an
innovative approach to bioassays, known as xMAP®
Technology. This groundbreaking technology enables
laboratories to multiplex bioassays, reducing time,
labor, and costs over traditional methods.
Luminex has been marketing the current
generation of xMAP Technology (formerly known as
LabMAP®) worldwide since 1999. Due to its openarchitecture platform, xMAP Technology can be
applied across a wide range of markets. In fact,
xMAP Technology-based systems are already in use
by leading clinical diagnostics and research
laboratories as well as major pharmaceutical and
biotechnology companies.
Escalating R&D spending, the evolution of
disease specific test panels, and the evolution of
pharmacogenomics are fueling the growth of the drug
discovery, clinical diagnostics and biomedical research
markets — including both genomics and proteomics
research. With this expansion of market opportunities,
Luminex is strategically positioned for sustained
growth and success.
Highlights
• Luminex develops an innovative biological testing
technology that delivers competitive advantages in
speed, precision, flexibility and cost
• Luminex offers an open-ended and broadly
enabling technology that’s already validated by
prominent customers worldwide
• Assay topic to come
• Luminex addresses a large global market in
which xMAP technology is poised to become the
industry standard
• Luminex expects to generate multiple, recurring
revenue streams via:
• Sales of instrumentation
• Sales of proprietary testing consumables known
as xMAP microspheres
• Royalties on products and tests developed for
use with xMAP technology
Luminex Assay Groups
Luminex Bioscience Group
The Luminex Bioscience Group, Inc., was
established in late 2005 to develop and
commercialize customer-driven xMAP-based
assays for channel partners and end-user
customers in key market segments.
Luminex Molecular Diagnostics
Luminex Molecular Diagnostics was formed in March
2007 when Luminex acquired Tm Bioscience of
Toronto, Canada. This division of Luminex Corporation
specializes in DNA-based research and diagnostics
and is focused specifically on the design, development,
manufacture, and commercialization of nucleic-acid
based testing products for genetic testing, personalized
medicine and infectious disease.
Market Opportunity
As of 2007, Luminex estimated that the combined
market for bioassays within its key market segments
to be approximately $3.8 billion. The life sciences
industry uses bioassays to detect the presence of
certain biochemicals, proteins or genes in a sample.
These types of tests are used extensively in drug
discovery, genetic analysis, pharmacogenomics,
clinical diagnostics and general biomedical research.
While other bioassay technologies are available in
each of these areas, xMAP Technology from Luminex
is flexible enough to be applied to all.
Each of these markets represents a significant
opportunity for Luminex due to:
• Increased R&D spending by pharmaceutical and
biotechnology companies
• A shift in R&D focus from discovery to functional
genomics and proteomics
• An increase in disease targets due to the success
of drug discovery efforts
• Evolution of pharmacogenomics and increased
demand for SNP (single nucleotide polymorphism)
studies
• The evolution of disease-specific test panels
Proprietary Technology
Luminex’s xMAP Technology is built on proven
technology – flow cytometry, microspheres, lasers,
digital signal processing and traditional chemistry –
that have been combined in a unique way. Systems
using xMAP Technology perform discrete bioassays
on the surface of color-coded beads known as
microspheres, which are then read in a compact
analyzer. The analyzer reads multiplexed assay results
The Luminex 100/200 System uses powerful, flexible
xMAP Technology to perform up to 100 bioassays at a time.
by identifying color differences between the beads as
well as the presence or absence of a fluorescent
reporter marker, all done in real time. And thanks to
its flexible, open-architecture design, xMAP Technology
can be configured to perform a wide variety of
bioassays quickly, cost-effectively and accurately.
Business Strategy
In order to establish xMAP technology as the
industry standard for performing bioassays,
Luminex is carrying out strategic plans to:
• Focus on large, fast-growing segments of the
life-sciences industry — including major
pharmaceutical companies, large clinical
companies and laboratories, in-vitro diagnostic
manufacturers, and major medical institutions
• Forge key partnerships to broaden and accelerate
market acceptance of xMAP Technology
• Enable partners to design their own tests using
our open-ended technology, thereby encouraging
the expansion of bioassay development and
providing additional competitive advantages
• Expand the functionality of the xMAP
Technology-based product line
Key Growth Strategies
• Enhance technology leadership with future
generations of xMAP Technology, expanding its
multiple testing capabilities and increasing
throughput
• Participate in the $20 billion clinical diagnostics
market by providing FDA compliant xMAP
Technology
• Convince prospective partners and customers
that xMAP Technology is an attractive alternative
to other approaches
• Manufacture products in sufficient quantities with
acceptable quality and cost
• Place and service sufficient quantities of
our products
Products
Consumables
Management Team
Luminex® 100/200™
The Luminex 100/200 System is a compact
analyzer that performs up to 100 bioassays
simultaneously, using a single drop of fluid –
therefore requiring very small patient samples
when compared with other testing technologies.
This system utilizes xPONENT and IS 2.3
software. The Luminex 100/200 and diagnostic
kits developed by Luminex strategic partners have
received 510(k) clearance from the FDA and can
be used on the Luminex 100/200 system for
diagnostic purposes.
Luminex® MicroPlex™ Microspheres
MicroPlex Microspheres (formerly named
Multi-Analyte Microspheres) are internally labeled
with fluorescent dyes and are available with either
carboxylate or avidin surface chemistries.
Patrick J. Balthrop Sr., President and
Chief Executive Officer
Russell W. Bradley, Vice President, Business
Development and Strategic Planning
Jeremy Bridge-Cook, Ph.D.
Vice President, Luminex Molecular Diagnostics
Douglas C. Bryant, Executive Vice President and
Chief Operating Officer
John C. Carrano, Ph.D., Vice President, Research
and Development
Harriss T. Currie, Vice President, Finance and
Treasurer Chief Financial Officer
Andy Ewing, Vice President, Technical Operations
Gregory J. Gosch, Vice President,
Luminex Bioscience Group
Darin S. Leigh, Vice President, Sales and
Marketing
Randel S. Marfin, Vice President,
Strategic Development
Oliver H. Meek, Vice President,
Quality Assurance and Regulatory Affairs
David S. Reiter, Vice President, General Counsel
and Corporate Secretary
Stephen Back, Vice President, Manufacturing
xPONENT® Software Solutions
xPONENT software brings the power of integration
and automation to laboratories and improves
workflow efficiency. xPONENT software combines
ease of use and flexibility to perform both protein
and nucleic acid testing on one Luminex system.
Assays
Luminex has identified key assay development
opportunities as a response to the market demand
for multiplexed solutions in emerging bio-assay
applications, providing effective solutions to partners
and customers.
microRNA Assays
FlexmiRTM Select
FlexmiRTM Human Panel
FlexmiRTM Mouse/Rat Extension Panel
FlexmiRTM Labeling Kit
FlexmiRTM Reagent Pak
FlexmiRTM Control Panel
Molecular Diagnostics Assays
CFTR IVD
xTAGTM RVP
Ashkenazi Jewish Panel*
CFTR 70+6*
Coagulation Panel*
P450-2C19*
P450-2C9*
P450-2D6*
P450-2C9+VKORC1*
*For Investigational Use Only. The performance characteristics of this
product have not been established.
UNITED STATES
Luminex Corporation
12212 Technology Blvd.
Austin, Texas 78727
United States
Tel: 512.219.8020
Fax: 512.219.5195
CANADA
Luminex Molecular Diagnostics
439 University Ave, Suite 900
Toronto, ON M5G 1Y8
Canada
Tel: 416.593.4323
Fax: 416.593.1066
Luminex® MagPlex™-C Microspheres
MagPlex-C Microspheres are superparamagnetic
carboxylated xMAP microspheres internally labeled
with fluorescent dyes. Magnetic separation offers
the best enablement of automation, eases samples
preparation and obviates the need for costly filter
plates.
Luminex® xTAG™ Microspheres
xTAG Microspheres (formerly FlexMAP
Microspheres) are pre-coupled with universal
oligonucleotides, optimized for isothermal multiplexing
(up to 100-plex) with minimal crosstalk. Capture
conditions are therefore standardized and
independent of content-specific reactions, allowing
ultimate flexibility in assay design.
Partners
Luminex has more than 50 partners in the
pharmaceutical drug discovery, clinical diagnostics
and biomedical research markets. They include:
• Abbott Molecular
• ARUP
• Asuragen
• Bio-Rad
• BMD
• Caymen Chemical
• Cogenics
• Celera Diagnostics
• Charles River Laboratories
• EMD Chemicals/Merck
• EraGen Biosciences
• Expression Analysis
• Fisher Healthcare
• Focus Diagnostics
• Innogenetics NV
• Immunetech
• INOVA Diagnostics
• Inverness Medical Professional Diagnostics
• Invitrogen Corporation
• Marligen
• Millipore
• MiraiBio
• One Lambda
• Panomics, Inc.
• PerkinElmer, Inc.
• QIAGEN, Inc.
• R&D Systems
• Radix Biosolutions
• Rules Based Medicine
• Tepnel Lifecodes
• Zeus Scientific
EUROPE
Luminex B.V.
Krombraak 15
4906 CR Oosterhout
The Netherlands
Tel: +31.162.408333
Fax: +31.162.408337
Investor Highlights
Headquarters: Austin, Texas
Founded: 1995
IPO Date: March 30, 2000
Nasdaq® Symbol: LMNX
Research Coverage:
America’s Growth Capital
Avondale Partners
Cannacord Adams
GARP Research & Securities
Jesup & Lamont Securities Corporation
Leerink Swann
Lehman Brothers
Pacific Growth Equities
Thomas Weisel Partners
Shares Outstanding at 3/31/08:
Approx. 36.7 Million
Contact Information
Luminex Corporation - Headquarters
12212 Technology Blvd.
Austin, TX 78727
Tel. 512.219.8020
Toll Free 888.219.8020 (in North America)
Fax 512.219.6325
www.luminexcorp.com
[email protected]
[email protected]
Statements made herein that express Luminex’s or management’s intentions, plans, beliefs,
expectations or predictions of future events that are forward-looking statements. These
words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “will” and similar expressions are
intended to further identify such forward-looking statements. It in important to note that the
company’s actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex’s actual results
or performance to differ materially include risks and uncertainties relating to fluctuations in
quarterly results due to a lengthy and unpredictable sales cycle, market demand and acceptance of Luminex’s products, the company’s dependence on strategic partners for development, commercialization and distribution of products, competition, Luminex’s ability to scaleup manufacturing operations, potential shortages of components and the timing of regulatory
approvals, as well as the risks discussed under the heading “Factors That may Affect Future
Results” in Luminex’s Form 10-K for the year ended December 31, 2003 as filed with the
Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this release, and Luminex expressly disclaims any intent, obligation or undertaking to update or revise such forward-looking statements to reflect any change in Luminex’s expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements are based.
www.luminexcorp.com
[email protected]
[email protected]
© 2008 Luminex Corporation. xMAP, Luminex 100, Luminex 200, Luminex HTS, xTAG, MicroPlex, FlexmiR, MagPlex and xPONENT are trademarks of Luminex Corporation.
Specifications and features subject to change without notice.
070808-080-01